posted on Oct, 25 2009 @ 04:29 AM
Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter
and bringing new focus on the market for vaccines. Large European pharmaceutical companies are reporting windfall sales from flu drugs and H1N1
Small biotechs are winning fresh attention from investors and governments looking for quick, less expensive ways of making flu vaccines to protect
their populations. And diagnostic companies have been growing revenues as doctors order more flu tests.
"Pretty much everyone who does something in influenza in has gained from it," said Hedwig Kresse, an infectious diseases analyst at Datamonitor in
London.Please visit the link provided for the complete story.
Let's take one example:
On Friday the U.S. Food and Drug Administration issued an emergency use authorization for an experimental new drug called peramivir, made by
Biocryst Pharmaceuticals Inc and licensed to Shionogi & Co Ltd.
The authorization allows the intravenous drug to be used in hospitalized patients who cannot take pills or inhale Relenza or when Tamiflu or Relenza
do not seem to be helping.Please visit the link provided for the complete story.
Sounds like a total surprise for investors!
But not for everyone
Banks are so
last season. Get with it. Pharmaceuticals are hip.
So what if the banks go down? At least the PTB/Goldman Sachs stockies now have somewhere to store their hard-earned cash.
OK, it may be on the back of mass/?forced? vaccinations, but hey, it's all for your good.
Ethical investments, anyone?..
edited title / kj
[edit on 31/10/2009 by kosmicjack]